Cizzle Biotechnology Holdings PLC (CIZ) - Total Liabilities
Based on the latest financial reports, Cizzle Biotechnology Holdings PLC (CIZ) has total liabilities worth GBX533.00K GBX (≈ $64.85 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cizzle Biotechnology Holdings PLC - Total Liabilities Trend (2006–2024)
This chart illustrates how Cizzle Biotechnology Holdings PLC's total liabilities have evolved over time, based on quarterly financial data. See CIZ working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Cizzle Biotechnology Holdings PLC Competitors by Total Liabilities
The table below lists competitors of Cizzle Biotechnology Holdings PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
QuiaPEG Pharmaceuticals Holding AB
ST:QUIA
|
Sweden | Skr8.81 Million |
|
Akoustis Technologies, Inc.
NASDAQ:AKTSQ
|
USA | $122.59 Million |
|
Mosman Oil and Gas Ltd
LSE:MSMN
|
UK | GBX955.96K |
|
Cerinnov Group SA
PA:ALPCV
|
France | €13.77 Million |
|
IMAC Holdings Inc
NASDAQ:BACK
|
USA | $6.27 Million |
|
Zoo Digital Group Plc
LSE:ZOO
|
UK | GBX17.03 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Cizzle Biotechnology Holdings PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Cizzle Biotechnology Holdings PLC.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cizzle Biotechnology Holdings PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cizzle Biotechnology Holdings PLC (2006–2024)
The table below shows the annual total liabilities of Cizzle Biotechnology Holdings PLC from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX410.00K ≈ $49.89 |
+120.43% |
| 2023-12-31 | GBX186.00K ≈ $22.63 |
+28.28% |
| 2022-12-31 | GBX145.00K ≈ $17.64 |
-33.49% |
| 2021-12-31 | GBX218.00K ≈ $26.52 |
+275.86% |
| 2020-12-31 | GBX58.00K ≈ $7.06 |
+489.07% |
| 2019-12-31 | GBX9.85K ≈ $1.20 |
-97.03% |
| 2018-12-31 | GBX331.00K ≈ $40.27 |
-85.88% |
| 2017-12-31 | GBX2.34 Million ≈ $285.20 |
+1.78% |
| 2016-12-31 | GBX2.30 Million ≈ $280.21 |
-14.32% |
| 2015-12-31 | GBX2.69 Million ≈ $327.05 |
-4.17% |
| 2014-12-31 | GBX2.81 Million ≈ $341.29 |
-10.04% |
| 2013-12-31 | GBX3.12 Million ≈ $379.37 |
-6.84% |
| 2012-12-31 | GBX3.35 Million ≈ $407.23 |
+66.19% |
| 2011-12-31 | GBX2.01 Million ≈ $245.05 |
+31.29% |
| 2010-12-31 | GBX1.53 Million ≈ $186.64 |
+131.02% |
| 2009-12-31 | GBX664.00K ≈ $80.79 |
+15.68% |
| 2008-12-31 | GBX574.00K ≈ $69.84 |
-20.83% |
| 2007-12-31 | GBX725.00K ≈ $88.21 |
-25.18% |
| 2006-12-31 | GBX969.00K ≈ $117.90 |
-- |
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more